» Articles » PMID: 18566412

CD73 Participates in Cellular Multiresistance Program and Protects Against TRAIL-induced Apoptosis

Overview
Journal J Immunol
Date 2008 Jun 21
PMID 18566412
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

The molecular mechanisms underlying the multiresistant phenotype of leukemic and other cancer cells are incompletely understood. We used expression arrays to reveal differences in the gene expression profiles of an apoptosis-resistant T cell leukemia clone (A4) and normally apoptosis-sensitive parental Jurkat cells. CD73 (ecto-5'-nucleotidase) was the most up-regulated gene in the resistant A4 cell clone. A4 cells displayed CD73 surface expression and significant ecto-5'-nucleotidase activity. The role of CD73 was confirmed by transfection of wild-type CD73 into native Jurkat cells, which led to specific resistance against TRAIL-induced apoptosis, but not other types of apoptosis. The protective role of CD73 was further confirmed by small interfering RNA-mediated down-regulation of CD73, restoring TRAIL sensitivity. CD73-mediated resistance was independent of enzymatic activity of CD73, but was reliant on the anchoring of the protein to the membrane via GPI. We suggest that the inhibition of TRAIL signaling works through interaction of CD73 with death receptor 5, as CD73 and death receptor 5 could be coimmunoprecipitated and were shown to be colocalized in the plasma membrane by confocal microscopy. We propose that CD73 is a component of multiresistance machinery, the transcription of which is activated under selective pressure of the immune system.

Citing Articles

Regulation of CD73 on NAD metabolism: Unravelling the interplay between tumour immunity and tumour metabolism.

Zhan J, Huang L, Niu L, Lu W, Sun C, Liu S Cell Commun Signal. 2024; 22(1):387.

PMID: 39090604 PMC: 11292923. DOI: 10.1186/s12964-024-01755-y.


The Clinical Significance of CD73 in Cancer.

Bach N, Winzer R, Tolosa E, Fiedler W, Brauneck F Int J Mol Sci. 2023; 24(14).

PMID: 37511518 PMC: 10380759. DOI: 10.3390/ijms241411759.


CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Independent Mechanism.

Liu W, Yu X, Yuan Y, Feng Y, Wu C, Huang C Adv Sci (Weinh). 2022; 10(6):e2206335.

PMID: 36563135 PMC: 9951332. DOI: 10.1002/advs.202206335.


Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity.

Gammelgaard O, Terp M, Renn C, Labrijn A, Hamaker O, Nielsen A J Immunother Cancer. 2022; 10(9).

PMID: 36096528 PMC: 9472124. DOI: 10.1136/jitc-2022-004554.


A Novel Anti-CD73 Antibody That Selectively Inhibits Membrane CD73 Shows Antitumor Activity and Induces Tumor Immune Escape.

Kellner M, von Neubeck B, Czogalla B, Feederle R, Vick B, Jeremias I Biomedicines. 2022; 10(4).

PMID: 35453575 PMC: 9031174. DOI: 10.3390/biomedicines10040825.


References
1.
Yamashita Y, Hooker S, Jiang H, Laurent A, Resta R, Khare K . CD73 expression and fyn-dependent signaling on murine lymphocytes. Eur J Immunol. 1998; 28(10):2981-90. DOI: 10.1002/(SICI)1521-4141(199810)28:10<2981::AID-IMMU2981>3.0.CO;2-D. View

2.
Soderstrom T, Nyberg S, Eriksson J . CD95 capping is ROCK-dependent and dispensable for apoptosis. J Cell Sci. 2005; 118(Pt 10):2211-23. DOI: 10.1242/jcs.02343. View

3.
Tran S, Meinander A, Eriksson J . Instant decisions: transcription-independent control of death-receptor-mediated apoptosis. Trends Biochem Sci. 2004; 29(11):601-8. DOI: 10.1016/j.tibs.2004.09.009. View

4.
Weller M . Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res. 1998; 292(3):435-45. DOI: 10.1007/s004410051072. View

5.
GUTENSOHN W, Resta R, Misumi Y, Ikehara Y, Thompson L . Ecto-5'-nucleotidase activity is not required for T cell activation through CD73. Cell Immunol. 1995; 161(2):213-7. DOI: 10.1006/cimm.1995.1029. View